We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AstraZeneca PLC on Monday said a breast cancer drug failed to significantly extend patients' lives, a second blow thi ...
d Daiichi Sankyo Co Ltd - Rahway, New Jersey-based and Tokyo-based pharmaceutical companies - Joint-developed monoclon ...
Daiichi Sankyo Co Ltd and AstraZeneca PLC on Friday reported "substantial clinical activity" for Enhertu in a recent ...
Daiichi Sankyo Co Ltd on Monday announced positive updates for Enhertu, with the cancer drug receiving support from U ...
AstraZeneca PLC and Daiichi Sankyo Co Ltd on Tuesday said their joint product Enhertu has received a third approval i ...
A life-extending drug for incurable breast cancer will not be made available on the health service in England after i ...
Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotama ...
Daiichi Sankyo Co Ltd on Wednesday said that strong sales of its flagship medicines drove revenue growth in its lates ...
AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved t ...
escription of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria) (Alliance News ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.92 | -6.07210626186 | 31.62 | 31.62 | 29.21 | 2562 | 30.35347436 | DE |
4 | -7.45 | -20.0538358008 | 37.15 | 37.979999 | 29.21 | 2058 | 32.75069063 | DE |
12 | -3.56 | -10.7035478052 | 33.26 | 38.7 | 29.21 | 1850 | 34.10899151 | DE |
26 | -0.81 | -2.65486725664 | 30.51 | 38.7 | 26.99 | 1350 | 33.28056965 | DE |
52 | 3.18 | 11.9909502262 | 26.52 | 38.7 | 22.86 | 1175 | 31.38498225 | DE |
156 | 2.34 | 8.55263157895 | 27.36 | 38.7 | 22.86 | 1136 | 31.21045966 | DE |
260 | 2.34 | 8.55263157895 | 27.36 | 38.7 | 22.86 | 1136 | 31.21045966 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions